Clinical observation of irbesartan combined with amiodarone on congestive heart failure with ventricular arrhythmias

Objective To investigate the clinical efficacy and safety of irbesartan and amiodarone in treatment of congestive heart failure with ventricular arrhythmia. Methods Seventy cases of congestive heart failure with ventricular arrhythmias were randomly divided into treatment group and control group, each of 35 cases. Two groups were treated with cardiac, diuretic, vasodilator and β-blockers and amiodarone 200 mg, 3 times a day orally, 1 to 3 times a week,two weeks later changed daily 3 times, gradually reduced to a maintenance dose. Irbesartan treatment group added in the initial daily dose of 80 mg, if there was no discomfort, changed daily 160 mg. Results After treatment, HR of two group′s patients were significantly reduced and the treatment group reduced more significantly than the control group,the difference was significant(P 0.05), LVEF increased than before treatment, and the treatment group increased more significantly than in the control group(P 0.05). The total effective rate was 91.4% in the treatment group after treatment, significantly higher than the control group of 74.3%(P 0.05). Observation group had lower blood pressure one case, one case of phlebitis, bradycardia one case. Control group had lower blood pressure in 3 cases, 3 cases of phlebitis, bradycardia two cases; The difference of incidence of adverse reactions in two groups was not significant(8.57% vs 22.86%, P0.05). Conclusion Irbesartan combined amiodarone in treatment of congestive heart failure with ventricular arrhythmias have better clinical efficacy and safety, worthy of promotion and application.